# IONC102

Source: https://onco.cc/drugs/ionc102/  
OnCo record `ionc102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IONC102 is an experimental RNA immunotherapy from iOncologi that is being tested in an early trial in glioblastoma.

## Summary

IONC102 is iOncologi's multilamellar RNA nanocomplex paired with AI-optimised, off-the-shelf antigens, which the company says is in a phase 1 trial in glioblastoma. The trial was not matched to a registry record in OnCo, so no cancer link is recorded.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline
- Code: IONC102
- Modality: RNA lipid nanoparticle immunotherapy
- Mechanism: RNA delivered in multilamellar lipid particles to prime a broad immune response, paired with off-the-shelf tumour antigens, as described by iOncologi.

## Sources

- iOncologi: https://ioncologi.com/

## Connected records

- companies: [iOncologi](https://onco.cc/companies/ioncologi/)

---
JSON: https://onco.cc/api/v1/entities/ionc102.json